Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus carboplatin and etoposide as perioperative therapy for resectable stage IIB-IIIA small cell lung cancer
ChiCTR2300077557Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: pathologic complete response. Started Nov 2023; status: recruiting.
02
Drugs
adebrelimabcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300077557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077557.